Scilex Holding Company (NASDAQ:SCLX) — Market Cap & Net Worth
Market Cap & Net Worth: Scilex Holding Company (SCLX)
Scilex Holding Company (NASDAQ:SCLX) has a market capitalization of $36.58 Million ($36.58 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23150 globally and #5061 in its home market, demonstrating a 3.27% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scilex Holding Company's stock price $5.37 by its total outstanding shares 7034737 (7.03 Million). Also see Scilex Holding Company (SCLX) total assets for a full breakdown of the balance sheet.
Scilex Holding Company Market Cap History: 2021 to 2026
Scilex Holding Company's market capitalization history from 2021 to 2026. Data shows change from $70.63 Million to $37.78 Million (-10.37% CAGR). Also see SCLX operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Scilex Holding Company is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #659 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2185 of 3165 |
Weight: Scilex Holding Company's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Scilex Holding Company Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scilex Holding Company's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Scilex Holding Company share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.84x
Scilex Holding Company's market cap is 2.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $70.63 Million | $31.32 Million | -$88.42 Million | 2.26x | N/A |
| 2022 | $28.07 Million | $38.03 Million | -$23.36 Million | 0.74x | N/A |
| 2023 | $14.35 Million | $46.74 Million | -$114.33 Million | 0.31x | N/A |
| 2024 | $3.00 Million | $56.59 Million | -$72.81 Million | 0.05x | N/A |
| 2025 | $85.82 Million | $30.25 Million | -$358.73 Million | 2.84x | N/A |
Competitor Companies of SCLX by Market Capitalization
Companies near Scilex Holding Company in the global market cap rankings as of September 18, 2026. Review SCLX intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Scilex Holding Company by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $1.03 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #19 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #44 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $1.03 Trillion | $1152.44 |
| #19 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $270.22 |
| #44 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $264.02 |
Scilex Holding Company Historical Marketcap From 2021 to 2026
Between 2021 and today, Scilex Holding Company's market cap moved from $70.63 Million to $ 37.78 Million, with a yearly change of -10.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $37.78 Million | -55.98% |
| 2025 | $85.82 Million | +2761.16% |
| 2024 | $3.00 Million | -79.10% |
| 2023 | $14.35 Million | -48.87% |
| 2022 | $28.07 Million | -60.26% |
| 2021 | $70.63 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Scilex Holding Company was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.58 Million USD |
| MoneyControl | $36.58 Million USD |
| MarketWatch | $36.58 Million USD |
| marketcap.company | $36.58 Million USD |
| Reuters | $36.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve… Read more